Merck Reports Earnings Under Shadow of Keytruda Patent Cliff. What to Expect.

Core Insights - The pharmaceutical maker's stock has decreased by 12% this year, indicating potential challenges in the market [1] Group 1 - The upcoming third quarter earnings report is anticipated, which may provide insights into the company's financial performance [1]